Overview of Dr. Nishihori
Dr. Taiga Nishihori is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from Hokkaido University Faculty of Medicine and has been in practice 18 years. Dr. Nishihori accepts several types of health insurance, listed below. He is one of 171 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
12902 Usf Magnolia Dr
Tampa, FL 33612Fax+1 813-745-6713- Is this information wrong?
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Icahn School of Medicine at Mount Sinai (Beth Israel)Residency, Internal Medicine, 2002 - 2006
Hokkaido University Faculty of MedicineClass of 1999
Certifications & Licensure
FL State Medical License 2010 - 2026
CT State Medical License 2006 - 2018- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma Start of enrollment: 2009 Jun 18
- Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
- Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD) Start of enrollment: 2010 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Mismatched donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide achieves comparable outcomes between racially and ethnically diver...Teresa Caprice, Wenyi Fan, Jongphil Kim, Rawan Faramand, Asmita Mishra, Lia Perez, Farhad Khimani, Aleksandr Lazar-Yan, Jose L Ochoa-Bayona, Hien Liu, Michael D Jain, ...> ;American Journal of Hematology. 2024 Mar 28
- Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma.Dean, E., Rawan G Faramand, Sae Bom Lee, Michael D Jain, Biwei Cao, Xuefeng Wang, Kai Rejeski, Marion Subklewe, Johannes F Fahrmann, Neeraj Y Saini, Samir M Hanash, Yu...> ;Blood Cancer Discovery. 2024 Mar 1
- Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy.Othman S Akhtar, Karnav Modi, Jongphil Kim, Lawrence Skelson, Eric Smith, Mohammed A Al-Jumayli, Martine Extermann, Gabriel De Avila, Nathan Parker, Omar Castaneda Pug...> ;Transplantation and Cellular Therapy. 2024 Mar 1
- Join now to see all
Journal Articles
- Case Report Haploidentical Transplantation as a Promising Therapy for Relapsed Hemophagocytic Lymphohistiocytosis in an Older Adult PatientTaiga Nishihori, Ernesto Ayala, ScienceDirect
Abstracts/Posters
- Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Ver...Taiga Nishihori, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts OutcomeTaiga Nishihori, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- CD34+ Cell Dose Influences Survival after Allogeneic Peripheral Blood Stem Cell Transplantation with Post-Transplant CyclophosphamideTaiga Nishihori, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple ...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
Moffitt Research of Selinexor for Relapsed/Refractory Multiple Myeloma Facilitates Recent FDA ApprovalJuly 24th, 2019
Professional Memberships
- Member
- Member
Hospital Affiliations
H. Lee Moffitt Cancer Center and Research InstituteTampa, Florida
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
BCBS Illinois PPO
CIGNA Open AccessCIGNA PPO
Coventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
